

FAQ - Oncologist

Q. Do you have papers proving results of TACE versus conventional treatment?

	Mean no. of Sessions	No. of Patients	Etiology HCV/ HBV/alcohol (%)	% with Cirrhosis (% with child A)	Okuda Stage I/II/III (%)	Segmental Portal Thrombosis (%)	Objective Responses (%)	Survival (%) 1 Year	2 Years
Lin et al. (1988)	-	63	-/80/-	Not described	Not described	Not described	-	-	-
TAE (Ivalon + Gelfoam powder/cubes)	(2.1 ±1)	21	-	-	-	-	13 (61.9)*	42	25
TAE +IV 5-fluorouracil (1g/m ² /5 days)	(1)	21	-	-	-	-	10 (47.6)*	20	20
IV 5-fluorouracil	-	21	-	-	-	-	2 (9.5)	13	13
Pelletier et al. (J 1990)	-	42	-/7/70	88	26/52/22	Not detailed	-	-	-
TACE (Gelfoam powder, doxorubicin [50mg])	(2)	21	-	-	-	-	7 (33) [†]	24	NA
Conservative Management	-	21	-	-	-	-	0	33	NA
Group d'Etude et de Traitement du Carcinome Hépatocellulaire (1995)	-	96	8/5/78	91 (100)	90/10/0	7 (7.2)	-	-	-
TACE (Gelfoam particles, cisplatin [70 mg])	(2.9)	50	-	-	-	-	7 (16) [†]	62	38
Conservative Management	-	46	-	-	-	-	2 (5) [†]	43	26
Bruix et al. (1998)	-	80	62/4/4	100 (82)	67/23/0	0	-	-	-
TAE (Gelfoam) + coils	(1.4)	40	-	-	-	-	22 (55)*	70	49
Conservative Management	-	40	-	-	-	-	0	72	50
Pelletier et al. (1998)	-	73	15/16/53	89 (76)	60/40/0	0	-	-	-
TACE (Gelfoam, cisplatin [2 mg/kg]) + tamoxifen	(2.8)	37	-	-	-	-	9 (24)	51	24
Tamoxifen	-	36	-	-	-	-	2 (5.5)	55	26
Lo et al. (2002)	-	79	-/80/-	Not described	47/53/0	21 (26)	-	-	-
TACE (1 Gelfoam, cisplatin [maximum 30mg])	(4.8)	40	-	-	-	-	11 (27) [†]	57	31
Conservative Management	-	39	-	-	-	-	1 (2.6)	32	11
Llovet et al. (2002)	-	112	85/6/7	100 (70)	65/35/0	0	-	-	-
TAE (Gelfoam)	(3.08)	37	-	-	-	-	16 (43) [§]	75	50
TACE (Gelfoam, doxorubicin [25-75mg/m ²])	(2.8)	40	-	-	-	-	-	-	-
Conservative Management	-	35	-	-	-	-	-	-	-

Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; TAE, arterial embolization; IV, intravenous; TACE, chemoembolization. Objective responses sustained for 1*, 2†, 3† and 6§ months.

